Blood Eosinophil Counts, Withdrawal of Inhaled Corticosteroids and Risk of COPD Exacerbations and Mortality in the Clinical Practice Research Datalink (CPRD)

References

• Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am J Respir Crit Care Med. 2017;195:557–582. doi: 10.1164/rccm.201701-0218PP.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. Lancet. 2007;370:786–796. doi: 10.1016/S0140-6736(07)61382-8.
   PubMed Web of Science ®Google Scholar
• Calverley PMA, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775–789.
   PubMed Web of Science ®Google Scholar
• Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;3:CD010115.
   PubMed Web of Science ®Google Scholar
• Vedel-Krogh S, Nielsen SF, Lange P, et al. Blood eosinophils and exacerbations in COPD: the Copenhagen general population study. Am J Respir Crit Care Med. 2015;193:965–974.
   Web of Science ®Google Scholar
• Pascoe S, Locantore N, Dransfield MT, et al. Blood eosinophil counts as markers of response to inhaled corticosteroids in COPD? - authors’ reply. Lancet Respir Med. 2015;3:e27. doi: 10.1016/S2213-2600(15)00259-3.
   PubMed Web of Science ®Google Scholar
• Watz H, Tetzlaff K, Wouters EFM, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med. 2016;4:390–398. doi: 10.1016/S2213-2600(16)00100-4.
   PubMed Web of Science ®Google Scholar
• Roche N, Chapman KR, Vogelmeier CF, et al. Blood eosinophils and response to maintenance COPD treatment: data from the FLAME trial. Am J Respir Crit Care Med. 2017;195:1189–1197.
   PubMed Web of Science ®Google Scholar
• Calverley PMA, Tetzlaff K, Vogelmeier C, et al. Eosinophilia, frequent exacerbations, and steroid response in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;196:1219–1221.
   PubMed Web of Science ®Google Scholar
• Price D, Rigazio A, Postma D, et al. Blood eosinophilia and the number of exacerbations in COPD patients. Eur Respir J. 2014;44:1697–1700.
   PubMed Web of Science ®Google Scholar
• GOLD. Global strategy for the prevention, diagnosis and treatment of chronic obstructive pulmonary disease (2019 Report). Global Initiative for Chronic Obstructive Lung Disease Inc. 2018 [cited 2018 Nov 15]. Available from: https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf.
   Google Scholar
• Vogelmeier C, Worth H, Buhl R, et al. “Real-life” inhaled corticosteroid withdrawal in COPD: a subgroup analysis of DACCORD. Int J Chron Obstruct Pulmon Dis. 2017;12:487–494.
   PubMed Web of Science ®Google Scholar
• Quint JK, Müllerova H, DiSantostefano RL, et al. Validation of chronic obstructive pulmonary disease recording in the Clinical Practice Research Datalink (CPRD-GOLD). BMJ Open 2014;4:e005540.
   Web of Science ®Google Scholar
• Herrett E, Gallagher AM, Bhaskaran K, et al. Data resource profile: clinical practice research datalink (CPRD). Int J Epidemiol. 2015;44:827–836. doi: 10.1093/ije/dyv098.
   PubMed Web of Science ®Google Scholar
• Taggar JS, Coleman T, Lewis S, et al. The impact of the Quality and Outcomes Framework (QOF) on the recording of smoking targets in primary care medical records: cross-sectional analyses from The Health Improvement Network (THIN) database. BMC Public Health 2012;12:1–11.
   PubMed Web of Science ®Google Scholar
• Rothnie KJ, Müllerová H, Hurst JR, et al. Validation of the recording of acute exacerbations of COPD in UK primary care electronic healthcare records. PLoS One. 2016;11:e0151357.
   PubMed Web of Science ®Google Scholar
• Padmanabhan S. CPRD GOLD Data Specification. 2015 [cited 2018 May 15]. Medicines & Healthcare Products Regulatory Agency. Available from: https://www.ed.ac.uk/files/atoms/files/cprd_gold_full_data_specification.pdf.
   Google Scholar
• Chapman KR, Hurst JR, Frent S-M, et al. Long-term triple therapy de-escalation to indacaterol/glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): a randomized, double-blind, triple-dummy clinical trial. Am J Respir Crit Care Med. 2018;198:329–339. doi: 10.1164/rccm.201803-0405OC.
   PubMed Web of Science ®Google Scholar
• Chatila WM, Thomashow BM, Minai OA, et al. Comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2008;5:549–555. doi: 10.1513/pats.200709-148ET.
   PubMedGoogle Scholar
• Dal Negro RW, Bonadiman L, Turco P. Prevalence of different comorbidities in COPD patients by gender and GOLD stage. Multidiscip Respir Med. 2015;10:24.
   PubMed Web of Science ®Google Scholar
• Franssen FME, Rochester CL. Comorbidities in patients with COPD and pulmonary rehabilitation: do they matter? Eur Respir Rev. 2014;23:131–141. doi: 10.1183/09059180.00007613.
   PubMedGoogle Scholar
• Divo M, Cote C, De Torres JP, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186:155–161. doi: 10.1164/rccm.201201-0034OC.
   PubMed Web of Science ®Google Scholar
• de Melo MN, Ernst P, Suissa S. Inhaled corticosteroids and the risk of a first exacerbation in COPD patients. Eur Respir J. 2004;23:692–697. doi: 10.1183/09031936.04.00049604.
   PubMed Web of Science ®Google Scholar
• Ernst P, Gonzalez A V, Brassard P, et al. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med. 2007;176:162–166. doi: 10.1164/rccm.200611-1630OC.
   PubMed Web of Science ®Google Scholar
• Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371:1285–1294. doi: 10.1056/NEJMoa1407154.
   PubMed Web of Science ®Google Scholar
• Vestbo J, Anderson JA, Brook RD, et al. Effect of treatment withdrawal on outcomes in the SUMMIT study. C41. Long acting bronchodilator therapy in COPD II. Am J Respir Crit Care Med. 2017:195:A5483–A5483.
   Web of Science ®Google Scholar
• Calzetta L, Matera MG, Braido F, et al. Withdrawal of inhaled corticosteroids in COPD: a meta-analysis. Pulm Pharmacol Ther. 2017;45:148–158. doi: 10.1016/j.pupt.2017.06.002.
   PubMed Web of Science ®Google Scholar
• Suissa S, Dell’Aniello S, Ernst P. Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study. Lancet Respir Med. 2018;15:415–417.
   Google Scholar
• Oshagbemi OA, Franssen FME, Braeken DCW, et al. Blood eosinophilia, use of inhaled corticosteroids, and risk of COPD exacerbations and mortality. Pharmacoepidemiol Drug Saf. 2018;27:1191–1199.
   PubMedGoogle Scholar
• Merinopoulou E, Raluy-Callado M, Ramagopalan S, et al. COPD exacerbations by disease severity in England. Int J Chron Obstruct Pulmon Dis. 2016;11:697–709. doi: 10.2147/COPD.S100250.
   PubMed Web of Science ®Google Scholar
• Vestbo J, Anderson JA, Brook RD, et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet. 2016;387:1817–1826.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Calverley PMA, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008;177:19–26.
   PubMed Web of Science ®Google Scholar
• Vestbo J, Fabbri L, Papi A, et al. Inhaled corticosteroid containing combinations and mortality in COPD. Eur Respir J. 2018;52:1801230.
   PubMed Web of Science ®Google Scholar
• Oshagbemi OA, Burden AM, Braeken DCW, et al. Stability of blood eosinophils in patients with chronic obstructive pulmonary disease and in control subjects, and the impact of sex, age, smoking, and baseline counts. Am J Respir Crit Care Med. 2017;195:1402–1404.
   PubMed Web of Science ®Google Scholar
• Landis SH, Suruki R, Hilton E, et al. Stability of blood eosinophil count in patients with COPD in the UK Clinical Practice Research Datalink. COPD J Chronic Obstr Pulm Dis. 2017;14:382–388.
   PubMed Web of Science ®Google Scholar
• Rothnie KJ, Müllerová H, Thomas SL, et al. Recording of hospitalizations for acute exacerbations of COPD in UK electronic health care records. Clin Epidemiol. 2016;8:771–782.
   PubMed Web of Science ®Google Scholar